tbuckley/cabot-search huggingface dataset:
RTHP-19. ANESTHETIC INDICATIONS, TECHNIQUES AND COMPLICATIONS FOR GAMMA KNIFE RADIOSURGERY
Authors: Anh Dang, Shital Vachhani, Tina Briere, Sujit Prabhu, Susan McGovern
Journal: Neuro-Oncology (2019)

Abstract PURPOSE We sought to describe our experience regarding anesthetic indications, techniques and complications with Gamma Knife radiosurgery (GKRS). METHODS We retrospectively evaluated the use of anesthesia for both adult and pediatric patients at a high-volume center. RESULTS Twenty-two adult cases and 10 pediatric cases were identified. For adult patients, the median age was 55.5 years. Pediatric patient ages ranged from 3 to 16 years. For adult patients, indications for sedation were claustrophobia (n=16), anxiety (n=4), chronic pain (n=1), and severe comorbidity (n=1). Twenty-five patients received general anesthesia with a secure airway (GA). Seven patients received total intravenous anesthesia with spontaneous ventilation (TIVA). One of these patients required placement of an airway after initial TIVA. The median sedation to treatment ratios for pediatric patients (3.76) and adult patients (4.06) did not significantly differ (P=0.49). However, the median sedation to treatment ratios for patients who received GA (4.08) was significantly higher than patients who received TIVA (1.88, P=0.0005). Anesthetic complications included cutaneous flushing, excessive secretions and airway obstruction that required unplanned placement of an airway, wheezing attributed to propofol sedation, and unspecified anesthetic issues that resulted in a MRI scan with a suboptimal time interval. All complications occurred in adult patients. CONCLUSIONS Gamma Knife radiosurgery with GA was associated with a longer sedation to treatment ratio compared to TIVA. However, despite the prolonged sedation time, use of GA was associated with few complications, none of which were severe and observed only in adult patients. Practitioners should consider the need for anesthesia in adult and pediatric patients who are intolerant to GKRS due to severe claustrophobia, anxiety, or pain when evaluating patients prior to GKRS. Due to the increased risk of respiratory complications in these patients, we recommend the use of general anesthesia with a secure airway despite the prolonged sedation time.
Left Ventricular Assist Device (LVAD) Implantation Transiently Increases Plasma TGF-β1 in Heart Failure Patients: Potential Impact of Lvad on Platelet Activation
Authors: Hendra Setiadi, Ahmed El-Banayosy, Erin Krueger, Karim Kouzbari, Gostynska Sandra, David Vanhooser, Aly El-Banayosy, Douglas Horstmanshof, James W Long, Jasimuddin Ahamed
Journal: Blood (2019)
Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group
Authors: Lisa Pleyer, Michael Pfeilstocker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Andreas Petzer, Clemens A. Schmitt, Sonia Vallet, Inga Mandac, Klaus Geissler, Wolfgang R. Sperr, Michael Leisch, Alexander Egle, Thomas Melchardt, Julia Fusinato, Gudrun Piringer, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Richard Greil
Journal: Blood (2019)
P1.08-A Sherlock Lung Tracing Lung Cancer Mutational Processes in Never-smokers
Authors: L. Mendoza, T. Zhang, M. Garcia-Closas, M. Abubakar, O. Arrieta, P. Hofman, D. Christiani, N. Lopez-Bigas, B. Rothberg, T. Peikert, D. Gordenin, L. Alexandrov, G. Getz, D. Wedge, M.T. Landi
Journal: Journal of Thoracic Oncology (2019)
Hepatic Coma Due to Liver Metastases
Authors: N. R. Pal, G. E. Whittingham, R. G. Paley
Journal: BMJ (1965)

Three cases of intestinal obstruction directly attributable to the use of a hydrophilic colloid laxative have been reported.A survey of the literature has revealed only two similar cases.The pathological process in this type of obstruction is discussed, and some suggestions are made with regard to its management.I wish to thank Mr. A. J. Wilson for permission to report the findings in Cases 1 and 3, and Mr. F. G. Hollands
High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients
Authors: Giorgia Chiodin, David Dutton, Enrica Antonia Martino, Samantha Drennan, Ian Tracy, Laura Ondrisova, Isla Henderson, Annalisa D'Avola, Christina Pitsillidou, Marek Mraz, Peter Johnson, Andrew Duncombe, Graham Packham, Andrew J Steele, Helen Parker, Silvia Bonfiglio, Lydia Scarfo, Lesley-Ann Sutton, Paolo Ghia, Matthew John Jerome Rose-Zerilli, Jonathan C Strefford, Freda K. Stevenson, Francesco Forconi
Journal: Blood (2019)
Is there a right control condition in mHealth trials? A critical view on pain medicine
Authors: Janosch A. Priebe, Thomas R. Toelle
Journal: npj Digital Medicine (2019)

When mobile health (mHealth) applications (apps) are investigated, the question of the proper control condition arises. Normally, the randomized controlled trial (RCT) is seen as the gold standard when testing efficacy of clinical interventions. Yet, mHealth apps rarely comprise innovative treatments but rather provide established treatments digitally. The classical RCT utilizing a placebo or waiting group condition may not always be the suitable methodology, since non-treatment is not appropriate if a disease urges treatment and the development of chronic disease needs to be prevented. The present commentary discusses conceivable control conditions in mHealth trials and illustrates their limitations.
Clinical-grade production and safe delivery of human ESC derived RPE sheets in primates and rodents
Authors: Karim Ben M'Barek, Stéphane Bertin, Elena Brazhnikova, Céline Jaillard, Walter Habeler, Alexandra Plancheron, Claire-Maëlle Fovet, Joanna Demilly, Mohamed Jarraya, Ana Bejanariu, José-Alain Sahel, Marc Peschanski, Olivier Goureau, Christelle Monville
Journal: Biomaterials (2019)
Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
Authors: Sheila K Pierson, Laura Katz, Christopher Sheild Nabel, Jason R Ruth, Sheila Diamond, Hrishikesh Karvir, Fanyi Zhang, Manjula P Reddy, Mary Guilfoyle, Craig Tendler, Frits van Rhee, Philip Beineke, Ana B Oromendia, David C Fajgenbaum
Journal: Blood (2019)
General Practice To-marrow
Authors: J. Fry
Journal: BMJ (1964)

Services of the Armed Forces.Next came the procession of the President and Officers of the B.M.A., with the Association's mace, which was placed on the high altar, then the Cathedral choir and clergy, followed by the civic procession.Finally to the fanfare of trumpets the Duchess of Gloucester entered, preceded by the Lord Lieutenant of the County, Lord Ashburton, and accompanied by the Lord Bishop and the Dean of Winchester.After the Dean of Westminster had delivered his address, and after an anthem and prayer, there were four lections from the New Testament, read from different parts of the Cathedral so that the congregation could
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Authors: Johannes B Goll, R. Coleman Lindsley, William F. Hooper, Rafael Bejar, Jason Walker, Robert Fulton, Gregory A. Abel, Tareq Al Baghdadi, H. Joachim Deeg, Amy E. DeZern, Benjamin Ebert, Pearlie Epling-Burnette, James M. Foran, Edward J. Gorak, Steven D. Gore, Rami S. Komrokji, Jane Jijun Liu, Jaroslaw P. Maciejewski, Eric Padron, Wael Saber, Daniel T. Starczynowski, Myron Waclawiw, Nancy DiFronzo, Mikkael A. Sekeres, Ling Zhang, Matthew J. Walter
Journal: Blood (2019)
Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Xiaowen Tang, Benigno C. Valdez, Qianqian Zhang, Yunju Ma, Haiping Dai, Jia Yin, Zheng Li, Ting Xu, Yang Xu, Jia Chen, Xiaming Zhu, Depei Wu, Borje S Andersson
Journal: Blood (2019)
Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction
Authors: Haiyang Yun, Shabana Vohra, Annalisa Mupo, George Giotopoulos, Daniel Sasca, Sarah J. Horton, Shuchi Agrawal-Singh, Eshwar Meduri, Faisal Basheer, Ludovica Marando, Malgorzata Gozdecka, Oliver M. Dovey, Xiaonan Wang, Paolo Gallipoli, Cameron Osborne, George S. Vassiliou, Brian J. P. Huntly
Journal: Blood (2019)
Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study
Authors: Liu Hui, Li Xuan, Ren Lin, Lan Deng, Fen Huang, Zhiping Fan, Danian Nie, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, Jieyu Ye, Hua Jin, Dongjun Lin, Liping MA, Jing Sun, Xiaojun Huang, Qifa Liu
Journal: Blood (2019)
Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Authors: Bryan Hambley, Eric Gehrie, Jonathan Webster, Margaret M. Showel, Lukasz P. Gondek, William Brian Dalton, Gabrielle T. Prince, Douglas E Gladstone, Ivana Gojo, Gabriel Ghiaur, Keith W. Pratz, B. Douglas Smith, Amy E. DeZern, Mark J. Levis
Journal: Blood (2019)
Anti-TNF, a magic bullet in cancer immunotherapy?
Authors: Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, Bruno Ségui
Journal: Journal for ImmunoTherapy of Cancer (2019)

Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These include colitis, which can be treated with anti-tumor necrosis factor (TNF) antibodies such as Infliximab. In a recent issue of the Journal for ImmunoTherapy of Cancer, Badran et al. reported that co-administering Infliximab together with ICB to five cancer patients prevents colitis recurrence, with four of them exhibiting overall disease stability. The basis for this treatment strategy stemmed from our pre-clinical demonstration that TNF contributes to resistance to anti-PD-1 therapy. In agreement with this concept, we have shown that TNF blockers improve the anti-tumor therapeutic activity of ICB in mice and based on these findings we are currently evaluating the combination in melanoma patients enrolled in the TICIMEL clinical trial. Herein, (i) we discuss the scientific rationale for combining anti-TNF and ICB in cancer patients, (ii) comment on the paper published by Badran et al. and (iii) provide the TICIMEL clinical trial design.
Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
Authors: Gerhard Held, Corinne Haioun, Roch Houot, Philippe Gaulard, Thierry Molina, Andreas Rosenwald, Marc André, Joerg Hoffmann, Martin Dreyling, Olivier Casasnovas, Herve Maisonneuve, Herve Tilly, Thomas Illmer, Stephanie Mayer, Heinz Kirchen, Paul La Rosée, Markus Loeffler, Marita Ziepert, Bettina Altmann, Viola Poeschel
Journal: Blood (2019)
Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms
Authors: Anna B. Halpern, Nicholas P Howard, Megan Othus, Paul C. Hendrie, Nikita Vashi Baclig, Sarah A Buckley, Mary-Elizabeth M. Percival, Pamela S. Becker, Bart L. Scott, Vivian G. Oehler, Terry B. Gernsheimer, Sioban Keel, Johnnie Orozco, Ryan D. Cassaday, Andrei R Shustov, Garrett Hartley, Verna L Welch, Elihu H. Estey, Roland B. Walter
Journal: Blood (2019)
TMOD-37. INTRAVITAL MONITORING DYNAMIC TUMOR MICRO-ENVIRONMENTAL EVOLUTION FOLLOWING HYPOXIA-INDUCED NECROSIS IN GLIOBLASTOMA
Authors: Steven Markwell, James Ross, Cheryl Olson, Felix Nunez-Santana, Constadina Arvanitis, Subhas Mukherjee, Daniel Brat
Journal: Neuro-Oncology (2019)

Abstract The onset of necrosis correlates with malignant progression in virtually all human cancers. Whether necrosis arises from or promotes rapid tumor expansion remains unknown, primarily due to insufficient model systems necessary for capturing these dynamic changes as they develop. In glioblastoma (GBM; WHO grade IV), the most malignant primary brain tumor, the development of central necrosis precedes rapid, radial expansion precipitously leading to patient mortality. While genetic alterations in GBM have been highly characterized, the resultant biological adaptations leading to accelerated tumor growth require further mechanistic investigation. The onset of necrosis dramatically changes the tumor microenvironment (TME), evolving from a sheet-like growth of infiltrating malignant cells undergoing gradual expansion to a complex 3-D microsystem comprising diverse cell types and spatially segregated signaling networks. To reveal the dynamic temporal and spatial changes promoting progression, we are generating mouse models that more appropriately capture events found in human gliomas, accounting for unique microenvironmental stressors often lacking in GBM animal models, specifically central necrosis. We developed a novel method combining hypoxia-induced focal necrosis within high-grade gliomas with intravital microscopy to study TME restructuring and its impact on glioma progression in real time. As translational applications, we are investigating how hypoxia and necrosis promote glioma stem cell (GSC) enrichment in their peri-necrotic niche and how the massive influx of tumor-associated macrophages (TAMs) promotes glioma progression. Our studies use both genetically characterized patient-derived orthotopic GBM xenografts in humanized mice, alongside an immunocompetent RCAS/tv-a model, to determine how antagonizing these processes impacts disease progression and outcomes across multiple GBM subtypes. Our preliminary data indicate substantial differences pre- and post-necrosis regarding GSC and TAM enrichment and their biological impact, however, these mechanisms have not yet been studied. Our models capture glioma growth dynamics, GSC enrichment, and TAM influx, facilitating innovative therapeutic interventions to improve patient outcome.
Diabetes Medications, Prostate-Specific Antigen Values, and the Chemoprevention of Prostate Cancer
Authors: Kyla N. Velaer, John T. Leppert
Journal: JAMA Network Open (2019)

Kerri Beckmann, PhD; Danielle Crawley, PhD; Tobias Nordström, PhD; Markus Aly, PhD; Henrik Olsson, MSc; Anna Lantz, PhD; Noor Binti Abd Jalal, MRes; Hans Garmo, PhD; Jan Adolfsson, MD; Martin Eklund, PhD; Mieke Van Hemelrijck, PhD
Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Authors: Franck Morschhauser, Herve Tilly, Aristeidis Chaidos, Tycel J. Phillips, Vincent Ribrag, Philip Campbell, Damaj Gandhi Laurent, Wojciech Jurczak, Pamela McKay, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles
Journal: Blood (2019)
INNV-39. THE IMPACT OF MULTIDISCIPLINARY MANAGEMENT ON THE OVERALL SURVIVAL OF GLIOBLASTOMA AND ANAPLASTIC GLIOMA PATIENTS IN THE ERA OF PRECISION MEDICINE-A COMMUNITY PHYSICIAN’S EXPERIENCE AND DILEMMA
Authors: Tulika Ranjan, Alexander Yu, Rodney Wegner, Stephen Karlovits, Linda Xu, Muhammad Hameed
Journal: Neuro-Oncology (2019)

Abstract The newer modalities of GBM treatment on the horizon are targeted therapy utilizing precision medicine, immunotherapy, Laser interstitial thermal therapy (LITT), ChemoID, CAR-T cell therapy, etc. There is always dilemma about referring a patient to the clinical trials which restrict the patient to one therapeutic agent Vs using a multi-disciplinary approach to improve patient’s survival. We present a single- institution retrospective data of the multidisciplinary management of our high grade glioma patients and their outcome. A chart review is being performed on high grade glioma patients (GBM, Gliosarcoma, Anaplastic Astrocytomas and Anaplastic Oligodendrogliomas) who had genomic alterations identified by commercial next generation sequencing. Thus far 100 patients had molecular profiling done at our institution and precision medicine was implemented in &gt;50 patients along with other treatments. Of 100 patients 82 were GBM and 18 were Anaplastic gliomas. There were 61 males and 39 females. MGMT methylation was seen in 36 patients and 12 patients had IDH1 mutation. The actionable mutations seen EGFR, EGFRvIII, TERT, PDGFR, CDKN2A-20, BRAF, PTEN, NF1- PD/PD-L1. The targeted therapy used were imatinib, sirolimus, afinotor, debrfenib, pembrolizumab, EGFR vIII vaccine. The chemotherapies utilized were BCNU,CCNU, CPT-11, Etoposide, carboplatin. Of 100 high grade glioma patients 8 patients underwent LITT, 24 patients received SRS, 58 patients received Avastin. All patients are being followed for overall survival (OS) and progression free survival (PFS-6) at this point. Of the 82 GBM patients 35 are still alive at a median 21 months. The median overall survival of the 47 dead GBM patients was 24 months. CONCLUSION: In high grade Glioma patients a multi-disciplinary approach may prolong the survival and the genomic analysis does impact the outcome of these patients. When we implement more than one therapy at the same time overall survival can’t be credited to one specific mode of therapy.
Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential
Authors: Rupert McShane, David S. Baldwin, R. Hamish McAllister-Williams, James M. Stone, David Taylor, Adam R. Winstock, Allan H. Young
Journal: American Journal of Psychiatry (2019)

TO THE EDITOR: Schatzberg (1) and others (2) are right to urge caution in the adoption of esketamine for treatment-resistant depression, but not only because of any effect on opiate pharmacology.The real risk lies in the reliance induced by rapid symptom relief followed by rapid relapse and in how this effect may intersect with socioeconomic status.Low income independently predicts poor response to repeated ketamine infusions (3), and partial responders tend to take esketamine more frequently and at shorter intervals than those who remit (4).Patients with low income may therefore be at greater risk of developing the tolerance that is warned of in the esketamine nasal spray data sheet (5).Low ability to pay, or other restrictions to access, may also increase switching to cheaper or illegal alternatives.By asking about previous ketamine use, as well as logging each esketamine treatment, the current esketamine nasal spray registry (6) can assess switching from ketamine to esketamine.However, it crucially fails to track the more likely switch from esketamine to medically administered ketamine, or to illegal ketamine.In the United Kingdom, we are advocating for the introduction of a single digital registry platform for collecting data on all new drugs with abuse potential.This includes esketamine, medically prescribed ketamine, and unwise, but potentially numerically dominant, selftreatment with nonprescribed ketamine.Postmarketing drug registries are well suited for examining longer-term effects of newly licensed products.However, patterns of switching from one drug with abuse potential to another cannot, self-evidently, be assessed in a registry that collects data about only one product.Collecting data on patients defined by their disease (e.g., treatmentresistant depression) would fail to capture information about those taking the drug off label.The problem requires a new class of "multiproduct" registries that can include off-label use and generic medications as well as new entrants.There is a pipeline of rapidly acting antidepressants in development, some of which have abuse potential, so stakeholders cannot afford to put decisions about the funding models for such registries into the "too difficult" basket.
Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Authors: Cyrille Hulin, Paul G. Richardson, Michel Attal, Hugh J. Goodman, Vadim A Doronin, Ivan Spicka, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Meral Beksac
Journal: Blood (2019)
Jobs come under threat at troubled Karolinska hospital in Sweden
Authors: Marta Paterlini
Journal: BMJ (2019)

Some 250 doctors and 350 nurses at the New Karolinska Hospital (NKS) in Stockholm have been warned that they could lose their jobs because of an unexpected deficit of SEK1.6bn (£128m; €150m; $165m) in the hospital’s finances for 2019.

NKS has been implementing a new operational model since October 2017, as well as moving to a new site.1 It is the result of an ambitious operation to set up one of the most advanced and specialised hospitals in Europe. The Swedish media have described it …
P2Y12 Inhibition by Clopidogrel Increases Periprocedural Bleeds in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Kensuke Matsushita, Benjamin Marchandot, Marion Kibler, Antonin Trimaille, Sebastien Hess, Lelia Grunebaum, Antje Reydel, Laurence Jesel, Patrick Ohlmann, Olivier Morel
Journal: Journal of the American College of Cardiology (2019)
Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia
Authors: Huafeng Wang, Jie Sun, Dandan Zhao, Hongyan Tong, Herman Wu, Xia Li, Yingwan Luo, Dan Dong, Tinisha McDonald, Anthony Stein, Monzr M. Al Malki, Flavia Pichiorri, Nadia Carlesso, Ya-Huei Kuo, Bin Zhang, Guido Marcucci, Ling Li, Jie Jin
Journal: Blood (2019)
Cancer- Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina
Authors: Ibrahim Saber, Maragatha Kuchibhatla, Alys Adamski, Lisa C. Richardson, Nimia Reyes, Karon Abe, Michele G Beckman, Elizabeth Thames, Bhavana Singh, Andrea Sitlinger, Ryan Schulteis, Thomas L. Ortel
Journal: Blood (2019)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
Authors: Alice Di Rocco, Arianna Di Rocco, Alessio Farcomeni, Luigi Petrucci, Giulia De Luca, Federico Mazzon, Maurizio Martelli, Robin Foà
Journal: Blood (2019)